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ABSTRACT
Title:

Utilizing Dexmedetomidine for a Patient with Prolonged Tourniquet Time to
Decrease Sympathetic Effects

Background: A 48 year old male presented with bilateral calcaneus fractures requiring open
reduction and internal fixation. Tourniquet times for the patient’s right and left
legs were 151 and 153 minutes respectively. It is known that prolonged
tourniquet applications of greater than 45-60 minutes results in an increased
sympathetic nervous system (SNS) response that is resistant to inhaled anesthetics
and narcotics. In this case study, we compared the patient’s blood pressure and
heart rate between the left and right calcaneus surgeries. A dexmedetomidine
infusion was administered during the left calcaneus surgery and not for the right
calcaneus.
Purpose:

To evaluate the use of a dexmedetomidine infusion for the attenuation of the
sympathetic nervous system response associated with prolonged tourniquet use.

Process:

A systematic search for articles published in the last ten years related to
tourniquet induced sympathetic nervous system response and dexmedetomidine
was performed using Pubmed and CINAHL. This information was synthesized
and compared to the case study in order to develop evidence based
recommendations for the use of dexmedetomidine in the attenuation of tourniquet
induced sympathetic nervous system response.

Results:

Dexmedetomidine does significantly attenuate the sympathetic nervous system
response related to prolonged tourniquet use.

Implications: Hemodynamic control of patients is essential to prevent organ damage, most
notably cardiovascular and neurological damage. Attenuation of the sympathetic
nervous system related to prolonged tourniquet use can prove to be a difficult task
for the anesthetist. Dexmedetomidine has been shown to be a viable option
to attenuate the SNS response and thus may positively impact patient outcome.
Keywords:

dexmedetomidine; tourniquet; tourniquet pain; sympathetic nervous system
response; orthopedic surgery; sympatholytic
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Utilizing Dexmedetomidine for a Patient with Prolonged Tourniquet Time to Decrease
Sympathetic Effects
Pneumatic tourniquets are used in extremity surgeries with the goals of decreasing blood
loss and allowing for better visualization of the surgical field. The lack of blood flow and oxygen
delivery to the extremity is not without consequence as it can lead to acidosis and tissue hypoxia,
which increases with the length of time the tourniquet is in use (Butterworth, Mackey, &
Wasnick, 2013). At tourniquet times of approximately 45-60 minutes, tissue acidosis and
hypoxia results in what is called tourniquet pain (Nagelhout & Plaus, 2014). Tourniquet pain
manifests itself with an increased sympathetic nervous system (SNS) response, which results in
hypertension and tachycardia (Nagelhout & Plaus, 2014). The exact pain pathway for tourniquet
pain is unknown, but it is resistant to narcotics and anesthetic gases (Nagelhout & Plaus, 2014).
The definitive treatment for tourniquet pain induced hypertension and tachycardia is to
shorten the tourniquet time (<45-60 minutes). This time variable is not controlled by the
anesthesia professional, but rather the surgeon. Additionally, short tourniquet times are not
always possible for specific procedures. Traditional treatments include the use of beta blockers to
decrease the SNS response, but their efficacy is limited, and the potential for hypotension
following tourniquet release is great. Allowing the blood pressure and heart rate to increase with
no intervention is another common option in healthy individuals since the SNS response is
transient and will resolve with tourniquet release. However, significant increases in blood
pressure and heart rate are associated with some risk, and may not be tolerated by individuals
with certain co-morbidities (e.g. congestive heart failure, coronary artery disease, abnormal
bleeding, stroke risk). Dexmedetomidine appears to decrease the SNS response associated with
tourniquet pain, which will be discussed further in this case report and literature review.
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Case Report
A 48-year-old, 71 kg, 174 cm male presented to the pre-operative holding room for open
reduction and internal fixation (ORIF) of bilateral calcaneus fractures. The injuries were
sustained 35 days earlier after a fall from a ladder. His past medical history was significant for
gastroesophageal disease (GERD), anxiety, depression, and one pack per day smoking habit. He
denied alcohol use. He was allergic to penicillin, which manifested as a rash. His surgical history
included lumbar fusion post L2 burst fracture and right tibia/fibula ORIF. He had no anesthetic
issues except he stated he sometimes wakes up “wild.” The patient had no neurological deficits.
Prior to his injuries the patient took no medications, but post fall he had been taking
hydrocodone 7.5 mg/ acetaminophen 325 mg two tablets every six hours, typically rating pain 79/10 before his medication administration.
Pre-operative airway evaluation included a Mallampati classification II, thyromental
distance greater than 6cm, inter-incisor distance greater than 4 cm, and full range of motion of
neck with no pain or stiffness. He was assigned an American Society of Anesthesiologists (ASA)
classification of 2. Plans were made for general anesthesia with and endotracheal tube.
The patient received an 18 gauge peripheral intravenous (IV) catheter in the pre-operative
area. Upon entry to the operating room (OR), the patient was connected to standard monitors,
and received midazolam 2mg and fentanyl 150 mcg IV. He stated he was in “a lot of pain,
10/10” upon moving to the OR table. The patient was preoxygenated with 100% oxygen via
mask for approximately 4 minutes. The patient then received the following medications IV:
lidocaine 60 mg, fentanyl 100 mcg, propofol 180 mg, and rocuronium 50 mg. The patient was
intubated utilizing a Macintosh #3 with a grade 1 view and a size 8.0 cuffed endotracheal tube
was placed with no issues. Placement was confirmed with end-tidal carbon dioxide (ETCO2) and

DEXMEDETOMIDINE AND TOURNIQUET USE

6

auscultation of bilateral clear lung sounds. General anesthesia was maintained with Sevoflurane
at a 2.2-3.0% expired concentration in a mixture of oxygen 1.5 L/min and air 1.5 L/min. A
bispectral index (BIS) monitor was applied, which read 40-50 throughout the case.
Prior to incision, an additional dose of fentanyl 250 mcg was administered with a
resulting blood pressure (BP) of 122/66 and a heart rate (HR) of 76 beats/minute. Immediately
after right leg tourniquet inflation and incision the patient’s BP increased to 151/76 and his HR
increased to 98. Sevoflurane was increased from 2.4% expired to 3.0% expired, and
hydromorphone 1 mg IV was administered. Fifteen minutes later the patient’s blood pressure
was 142/74 with a heart rate of 90. After another 30 minutes (45 minutes total tourniquet time)
the patients BP increased to 162/82 with a HR of 105. The BIS was 40-42 at this time. Another
2mg hydromorphone IV was given resulting in a BP of 136/80 and a HR of 84. At a total
tourniquet time of 90 minutes the patients BP was 155/82 with a HR of 102 and a BIS of 40-45.
At total tourniquet time of 104 minutes the patient’s BP was 164/91 with a HR of 105. At this
time 10 mg Labetalol IV was administered resulting in a BP of 147/78 and a HR of 97. At a
tourniquet time of 122 minutes the patient’s BP was 163/96 with a HR of 104. Labetalol 5 mg IV
was given at this time resulting in a BP of 152/91 and HR of 99. The patient’s BP and HR slowly
increased to 164/94 and 105 respectively until the release of the tourniquet at a total tourniquet
time of 151 minutes. Immediately upon tourniquet release the patient’s BP decreased to 124/72
and HR decreased to 82.
During surgery, it was discussed with the surgeon that the left calcaneus was more
extensively damaged and may require a longer tourniquet time. Due to the expected long
tourniquet time and narcotic requirements of the patient, we decided to start a dexmedetomidine
infusion prior to the ORIF of the left calcaneus. The patient’s BP prior to tourniquet inflation and
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incision was 118/70 with a HR of 78. A dexmedetomidine bolus was not given and the infusion
was started at 0.7 mcg/kg/hr. Total tourniquet time was 153 minutes with a patient max BP of
148/82 and HR of 95. No additional narcotics or labetalol was given, and Sevoflurane was
slowly decreased from an expired concentration of 3.0% to 2.0%.
Dexmedetomidine was discontinued at approximately 20 minutes prior to the end of the
procedure. Ondansetron 4mg IV was given at this time. Prior to extubation the patient produced
tidal volumes of 400-600 ml at a rate of 14 breaths/min and opened eyes periodically to voice.
The endotracheal tube was removed and oxygen at 4 LPM via nasal cannula was applied. The
patient was then brought to the post anesthesia care unit (PACU). Report was given and care was
transferred. Upon entry to the PACU the patient was drowsy but denied pain. One hour later, the
patient was alert and calm rating pain 5/10, for which he was receiving IV fentanyl.
Discussion
Tourniquet Pain
Tourniquet pain is the result of mechanical compression to the underlying muscles,
nerves, and blood vessels, along with ischemia to the distal tissues (Estebe, Davies, and Richebe,
2011). The specific metabolic and neuronal pathways that result in tourniquet pain are unknown,
but they result in an aching pain that is associated with C-fibers, and a tingling/burning pain
associated with A-delta fibers (Nagelhout & Plaus, 2014). Tourniquet pain is better controlled if
adequate anesthesia is obtained prior to the application of the tourniquet, because of a
hyperalgesia phenomenon, which results in an increased sensitization of pain receptors if they
are previously activated (Estebe et al., 2011). Despite adequate anesthesia, tourniquet pain
typically presents with a dull aching pain (C-fiber pain) at about 45-60 minutes (Nagelhout &
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Plaus, 2014). As the duration of tourniquet time increases, so does the intensity of tourniquet
pain.
SNS response to tourniquet use. The increased blood pressure and heart rate associated
with prolonged tourniquet use are a result of the increased SNS response associated with
tourniquet pain (Estebe et al., 2011). Tourniquet induced hypertension, which is defined as a
blood pressure greater than 30% of baseline is found in approximately 67% of patients who
undergo general anesthesia for lower extremity surgery requiring a tourniquet (Li et al., 2015).
The SNS is activated by the acute pain pathway and results in the release of the catecholamines
epinephrine and norepinephrine (Nagelhout & Plaus, 2014).
This case report depicts a clear picture of this SNS response with the tourniquet time on
the right leg. As the case progressed and total tourniquet time increased, the patient’s heart rate
and blood pressure increased despite multiple doses of narcotics and labetalol. There was
periodic decreases in heart rate and blood pressure with interventions, but overall the SNS
response became more difficult to control the longer the tourniquet was in place.
Tourniquet Time
The maximum safe length of tourniquet time is controversial. Nagelhout & Plaus (2014)
states that tourniquet time should not exceed two hours in order to avoid severe complications
associated with ischemia. In a meta-analysis performed by Estebe et al. (2011), it is
recommended that tourniquet time not exceed one hour in order to avoid ischemic injury. They
further noted that up to 3 hours of tourniquet time does not typically result in irreversible
ischemic damage, but over 1 hour can result in sublethal tissue injury (Estebe et al., 2011).
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Dexmedetomidine
Mechanism of action. Dexmedetomidine is an alpha 2 adrenergic agonist with sedative
properties, which reduces the SNS response by decreasing the release of norepinephrine and
epinephrine into the circulation, thus decreasing blood pressure and heart rate (Lao, Tsai, Su,
Kwok & Huang, 2013). This makes it an ideal adjunct for patients requiring prolonged
tourniquet application, as was demonstrated by the patient’s heart rate and blood pressure
comparisons between his right and left calcaneous surgeries in the case study. Dexmedetomidine
possesses the additional benefits of analgesia, reduction of postoperative shivering, and sedation
with minimal effect on respirations (Lao et al, 2013). The drug also shows some benefit in
reducing the effects of ischemic/perfusion injuries on the cellular level, which may results from
extended tourniquet time (Cai, Xu, Yan, Zhang & Lu, 2014).
Emergence delirium. Dexmedetomidine is noted to decrease emergence delirium in
elderly patients. In a randomized double blinded control study done by Kim et al. (2015), 115
patients over the age of 65 ASA I-II receiving lower extremity orthopedic surgery were
examined. Half of the patients received a dexmedetomidine infusion of 0.4 mcg/kg/hr and half
did not. The incidence of emergence agitation/delirium was 11.1% in the group that received
dexmedetomidine infusions compared to 75% in the control group (Kim et al., 2015). Emergence
delirium is common in elderly patients receiving orthopedic surgery, and can lead to self-injury,
increased hemorrhage, and prolonged PACU/hospital stays (Kim et al., 2015).
There were no studies found examining the incidence of emergence delirium in
orthopedic surgery with the use of dexmedetomidine in the age range that would be applicable to
the patient in this case report. However, the anti-emergence delirium effects of dexmedetomidine
appeared to be beneficial for the case. During the preoperative interview of the case study
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patient, he stated he has been “wild” during emergence from anesthesia in the past. His
emergence was smooth with no issues. He was calm throughout extubation to discharge from
PACU.
Side effects. The main side effects of dexmedetomidine include bradycardia, heart block,
and hypotension (Skidmore-Roth, 2014). These side effects appear to be dose dependent, but can
be severe enough to cause asystole and possible death (Jaideep & Bhargava, 2015). It should be
used cautiously in patients with severe hypotension, bradycardia, hypersensitivity, and
dysrhythmias (Skidmore-Roth, 2014). Typical adult administration includes a loading dose of 1
mcg/kg over ten minutes followed by a continuous infusion of 0.2-0.7 mcg/kg/hr (SkidmoreRoth, 2014). Infusions of up to 1.5 mcg/kg/hr have been shown to be safe (Cai et al., 2014).
Half-life. Dexmedetomidine has a rapid onset with an elimination half-life of 2 hours
(Skidmore-Roth, 2014). It is 94% protein bound, metabolized by the liver, and excreted by the
kidneys (Skidmore-Roth, 2014). Dosages should be reduced in patients with abnormal kidney
and liver function (Butterworth, Mackey, & Wasnick, 2013).
Cost. It is important for anesthesia professionals to consider cost when formulating a plan
of care. Pricing for dexmedetomidine is approximately $541.28 for 200 mcg in 50 ml normal
saline (D. Schmidt, personal communication, March 25, 2016).
Stable Hemodynamics
Adequate tissue perfusion is perhaps one of the most important goals for anesthesia
professionals. One important way that we are able to judge adequate tissue perfusion is through
blood pressure (Lonjaret, Lairez, Minville, & Geeraerts, 2014). Hypertension during the
intraoperative period has been associated with myocardial ischemia, cerebral vascular
complications, and increased bleeding (Lonjaret et al., 2014). Patients with bleeding disorders
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and vascular disease are at an even higher risk of developing these complications due to
intraoperative hypertension (Lonjaret et al., 2014). Lonjaret et al. (2014) also states, “in patients
with known coronary artery disease or at high risk for coronary artery disease who are
undergoing noncardiac surgery, preoperative hypertension increases risk for death by 3.8 times”
(p. 50). Special care should be taken to maintain stable blood pressure in patients with these risk
factors. It is difficult to determine an exact point in which hypertension is detrimental, and it is
most likely patient specific. However, Lonjaret et al. (2014) defines intraoperative hypertension
as being > 160 mmHg systolic and/or > 100 mmHg diastolic. They further defined a SBP ≥ 180
and a DBP ≥ 120 as being a hypertensive urgency requiring prompt intervention (Lonjaret et al.,
2014). Maintaining a stable blood pressure throughout the perioperative period likely will help to
maintain tissue perfusion. Ultimately, this potentially will improve patient outcomes by
decreasing the risk of cardiovascular injury, stroke, and bleeding.
Increased heart rate can also be detrimental to tissue perfusion, specifically tissue
perfusion of the heart. The heart is perfused during diastole. An increased heart rate not only
increases the oxygen demand of the heart, it decreases the length of time the heart is able to
perfuse (diastole). Tachycardia has also been associated with atherosclerotic plaque disruption
leading to acute myocardial infarction (MI) (Wong & Erwin, 2016). Patients with coronary
artery disease are especially at danger for MI with the contributing factor of an increased heart
rate (Wong & Erwin, 2016). A heart already stressed from coronary artery disease may be
pushed over the edge into infarction with the increased demands associated with tachycardia.
Dexmedetomidine Use in Surgery Requiring a Tourniquet
Lao et al. (2013) performed a prospective, randomized, placebo controlled, double
blinded study on the sympatholytic effects of dexmedetomidine in patients undergoing general
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anesthesia for lower limb surgery requiring a tourniquet. Seventy-two healthy adults were
included in this study with 36 in the dexmedetomidine group who received a loading dose of 0.8
mcg/kg over 10 minutes followed by an infusion of 0.4 mcg/kg/hr, and 36 in the control group
who received saline. After induction and prior to tourniquet application, patients in the
dexmedetomidine group received their dexmedetomidine bolus and infusion, while the control
group received normal saline. The tourniquet was then inflated to a pressure of 300-350 mmHg.
Regardless of group, patients with blood pressure >160/90 for over five minutes received 5 mg
of nicardipine repeated every five minutes as needed, and patients with SBP <90 or MAP <70
received ephedrine every five minutes in incremental doses. Hemodynamic parameters were
measured and compared between the groups at inflation and every 15 minutes there after until
tourniquet deflation. They found the average blood pressure was significantly lower in the
dexmedetomidine group at inflation until about 90 minutes. At 90 minutes there was no
significant difference in blood pressure. The blood pressure was again significantly lower in the
dexmedetomidine group when the tourniquet was released.
The researchers determined that dexmedetomidine does in fact attenuate the increases in
blood pressure associated with prolonged tourniquet use. They hypothesized that the meeting of
the patients’ blood pressure at the 90 minute mark was due to the steadily increasing SNS
response, and that a titrating the dexmedetomidine infusion up would most likely help to combat
the increased SNS response. Heart rate was significantly lower in the dexmedetomidine group at
all points during tourniquet use. The average heart rate was 67-80 beats/min through tourniquet
release in the dexmedetomidine group compared to 75-90 beat/min in the control group.
Nicardipine supplementation was increased in the control group at an average of 0.4 mg ± 1.6
standard deviations (stdv) compared to 0.1 mg ± 0.3 stdv average for the dexmedetomidine
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group. Ephedrine supplementation was increased in the dexmedetomidine group at 3.6 mg ± 5.8
stdv compared to 0.8 mg ± 3.7 stdv for the control group. This increase in ephedrine use was
especially noted in the immediate period after the bolus dose. The researchers discussed that the
synergistic effects of the inhalation agents, fentanyl, and midazolam, along with the
dexmedetomidine, would probably warrant a smaller loading dose (Lao et al., 2013).
No loading dose was given to the patient in this case report involving bilateral calcaneous
repair because the providers believed that the previous 3 hours of anesthetic drugs plus a loading
dose may precipitate a hypotensive and/or a bradycardic event. However, dexmedetomidine does
have rapid distribution with a steady state volume of distribution of approximately 118 L
(Nagelhout & Plaus, 2014). This suggests the need for a bolus in order to obtain consistent drug
levels in the blood stream.
The patient in the case report showed improved results in the attenuation of the SNS with
the administration of the dexmedetomidine infusion without a bolus on the left leg compared to
no dexmedetomidine infusion with the right leg. This is a peculiar case however, because the
dexmedetomidine infusion was started in the middle of the surgery after the patient had already
received approximately 3 hours of general anesthesia.
Another placebo controlled, randomized, double blind prospective study by Lu et al.
(2013) examined the sympatholytic effects of dexmedetomidine. This study looked at 37 healthy
individuals split into a dexmedetomidine group who received a bolus of 0.5 mcg/kg bolus prior
to tourniquet inflation of 300 mmHg with no continuous infusion, compared to a control group
who received saline. Blood pressure and heart rate where measured and compared every 10
minutes for a total of 60 minutes and at tourniquet deflation. They noted that there was no
significant changes in HR between the groups until the tourniquet release time, where the
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average HR of the control group was approximately 90 beats/min and the dexmedetomidine
group was 78 beats/min. The blood pressure for the dexmedetomidine group was very stable at
approximately 120/63 throughout the first 60 minutes and upon tourniquet release.
Comparatively, the average SBP and DBP of the control group increased significantly at the 40,
50, and 60 minute marks with average pressures of 138/78, 142/81, and 150/90 respectively (Lu
et al., 2013).
These findings appear to be consistent with the increased tourniquet pain at the 45-60
minute mark. Lu et al. (2013) discussed the importance of blunting the pain and sympathetic
response to prolonged tourniquet use prior to its manifestation, because once it begins the
feedback loop is difficult to control. This article seems to support the use of a dexmedetomidine
bolus, which was not used during this papers presented case study. Unfortunately the Lu et al.
(2013) study did not examine the hemodynamic effects of the dexmedetomidine group and the
control group after 60 minutes. It would be beneficial to determine if and/or when the
dexmedetomidine bolus would wear off, or the SNS response would overcome the sympatholytic
effects of the bolus. The stable blood pressure and heart rate of the two groups up to the 40
minute mark indicates that total tourniquet time below this period would not warrant the need for
dexmedetomidine.
The previously discussed research studies excluded patients with a history of
hypertension. Hypertension is a common finding in patients that receive orthopedic surgery of
the lower extremity. Li et al. (2015) performed a double blinded, placebo controlled study of 80
patients in which 43 of them had a history of hypertension. The patients were divided into
hypertensive and non-hypertensive groups and within those groups the patients were randomly
assigned to a dexmedetomidine group who received a bolus of dexmedetomidine of 1 mcg/kg
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over 20 minutes followed by an infusion of 0.4 mcg/kg/hr until tourniquet release and a control
group that received saline. They defined hypertension as > 160 mmHg systolic and determined
the incidence of its occurrence. The incidence of hypertension was 71.8% for the control group
and 34.1% for the dexmedetomidine group, which was significant. In the control group the
incidence of hypertension was 66.7 % for the non-hypertensive patients and 77.8% for the
hypertensive patients, which was not significant. In the dexmedetomidine group the incidence of
hypertension was 12.5% of non-hypertensive patients compared to 48.0% of hypertensive
patients, which was significant, but the incidence of hypertension in the hypertensive population
between the control and dexmedetomidine group was substantial (Li et al., 2015).
This study shows that dexmedetomidine is beneficial in the patient population that has a
history hypertension. However, there might be some consideration in increasing the
dexmedetomidine rate in those populations that have hypertension. Theoretically, an increased
rate of dexmedetomidine would increase the sympatholytic response and decrease patients’
blood pressure.
Dexmedetomidine is not necessary for all patients having surgery requiring tourniquet
use. Some individuals show no significant increases in heart rate and blood pressure depending
on the length of the procedure and patient specific responses. It is sometimes difficult to predict
the length of tourniquet application for certain procedures, and we are unable to determine the
timing at which patients will have an exaggerated SNS response. Allee et al. (2011) discussed
three case studies where they administered dexmedetomidine boluses of 0.5 mcg/kg over two
minutes after patients exhibited tachycardia and hypertension secondary to tourniquet pain.
These studies demonstrated that dexmedetomidine is useful for tourniquet pain induced
hypertension and tachycardia even after its manifestation. In all three studies, the providers first
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attempted to administer more narcotics and increase the anesthetic gases with no results. After
the administration of dexmedetomidine 0.5 mcg/kg over 2 minutes all of the patients’ blood
pressures and heart rates returned to baseline. In one of the three cases, the patient’s vital signs
remained stable throughout the procedure after one dose. For the other two procedures the
patients’ blood pressure and heart rate started to increase over the next 15-20 minutes, so a
second bolus of dexmedetomidine 0.5 mcg/kg over 2 minutes were given followed by an
infusion of 0.5/mcg/kg/hr with good results maintaining blood pressure and heart rate close to
baseline. After tourniquet release there were no significant drops in the patients’ blood pressure
or heart rate for any of the cases.
Although there seems to be some advantage to starting dexmedetomidine prior to the
manifestation of tourniquet induced hypertension and tachycardia, starting dexmedetomidine as
needed appears to be a viable option. This was also demonstrated with the patient in this case
report, where there appeared to be obvious benefits to attenuating the sympathetic response
attributed to tourniquet pain despite starting the dexmedetomidine infusion half way through the
procedure.
Adverse Reactions
Hypotension and bradycardia were the most common adverse reaction noted in the
research studies involving the use of dexmedetomidine for the attenuation of tourniquet pain (Lu
et al., 2013; Lao et al., 2013; Li et al., 2015). The hypotension and bradycardia appeared to be
dose dependent. The Lao et al. (2013) study, which used a dexmedetomidine starting bolus of 0.8
mcg/kg over ten minutes, had the highest requirement of ephedrine and atropine use compared to
its control group. The Lu et al. (2013) study, which used a staring bolus of 0.5 mcg/kg over ten
minutes, showed no significant difference between the control group and dexmedetomidine
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group in the requirement of rescue drugs for bradycardia and hypotension. However, both of
these sample sizes are relatively small and more research is needed to determine the most
appropriate loading dose. When hypotension and bradycardia are encountered with the use of
dexmedetomidine, it responds well to the administration of ephedrine and/or anticholinergics (Lu
et al., 2013; Lao et al., 2013; Li et al., 2015).
Caution is required when administering dexmedetomidine in patients who present with a
heart less than 60 and/or are hypovolemic. Jaideep and Bhargava (2015) describe a case of
prolonged asystole in a patient who received a dexmedetomidine infusion of 0.5 mcg/kg/hr after
spinal anesthetic. The patient was a healthy 31 year old receiving a complex repair of his cruciate
ligaments requiring a total tourniquet time of 150 minutes. His baseline heart rate was 55
beats/min and blood pressure of 113/71. After the initiation of the infusion his heart decreased to
47-52 beats/min, but there was no significant decrease in blood pressure. At the completion of
the surgery the tourniquet was deflated and the patient’s heart rate quickly decreased to 30
beats/min, 0.6 mg atropine IV where given. The patient was awake at this time and went
unconscious followed by a 10 second episode of asystole. The patient’s heart responded and he
returned to consciousness with a heart rate of 60 beats/min. Jaideep and Bhargava (2015) warn of
the use of dexmedetomidine in those patients that possess good vagal tone and have a slow
baseline heart rate. The combination of the patient’s vagal tone, the sympathectomy associated
with the spinal anesthetic, and the quick changes in fluid status and acidosis associated with the
release of the tourniquet, along with the bradycardic effects of dexmedetomidine most likely led
to the patient’s asystole.
An additional adverse effect to consider with the use of dexmedetomidine in surgery is
the prolongation of time in the post anesthesia care unit (PACU). PACU time is expensive and
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any intervention that prolongs it must be examined carefully to insure the benefits justify the
cost. Although there are no research articles that examine PACU time in adult patients when
dexmedetomidine is added to their anesthetic, Li et al. (2015) noted that PACU times for
dexmedetomidine patients were most likely longer compared to the control group, but the design
of their study did not allow for scientific confirmation of this. Kim et al. (2015) examined
emergence in elderly patients receiving dexmedetomidine and noted that the time from anesthetic
cessation to eye opening for a control group was approximately 10 minutes compared to a
dexmedetomidine group being 14 minutes. Minutes to extubation was approximately 11 minutes
for the control group compared to 15 minutes for the dexmedetomidine group. More research
needs to be done on the time costs if any when adding dexmedetomidine to an anesthetic.
Dexmedetomidine and Ischemia/Reperfusion Injuries
Prolonged tourniquet use can lead to ischemia, the production of free oxygen radicals,
and the increase of pro-inflammatory products (Estebe et al., 2011). Subsequent reperfusion
leads to oxidative stress and the distribution of the pro-inflammatory products throughout the
systemic circulation (Estebe et al., 2011). This occurrence is known as an ischemic/reperfusion
injury. Dexmedetomidine has been shown to attenuate this type of injury. Dexmedetomidine has
antioxidant abilities that neutralize the formation of free oxygen radicals (Cai et al., 2014).
Dexmedetomidine also seems to effect gene expression resulting in an increase of
antiapoptotic proteins and decrease in proapoptotic proteins resulting in less cellular death (Cai
et al., 2014). The sympatholytic effects of the drug also reduces the metabolic demands of the
tissues resulting in ischemic resistance (Cai et al., 2014). Dexmedetomidine also diminishes the
detrimental inflammatory response by decreasing the production of leukocytes (Cai et al., 2014).
Yagmurdur et al. (2008) compared patients who received dexmedetomidine and regional
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anesthesia for upper extremity surgery to patients who received regional anesthesia only, and
found a significant reduction in ischemic/reperfusion injury markers. However, a study done by
Bostankolu et al. (2013) noted no difference in ischemic injury markers with the addition of
dexmedetomidine in patients having general anesthesia for lower extremity surgery with a
tourniquet. The main difference between these two studies was the use of general anesthesia
compared to regional anesthesia. Many of the anesthetics that practitioners use for general
anesthesia attenuate ischemia/reperfusion injuries (Bostankolu et al., 2013). Studies have shown
that propofol, thiopental, and sevoflurane all have the ability to decrease ischemic/reperfusion
markers (Bostankola et al., 2013). Dexmedetomidine does have benefits for ischemia/reperfusion
injuries, but more research is required to determine if those benefits are significant when
compared to other general anesthetics.
Alternative Therapies for Tourniquet Pain
The most common therapy used to combat the SNS response from tourniquet pain is the
administration of beta adrenergic blockers. Common beta blockers utilized in anesthesia practice
include labetalol and esmolol.
Labetalol. Labetalol is typically administered in 5-10mg doses until desired effect is
reached. The greatest concern with labetalol use to treat hypertension and tachycardia due to
tourniquet pain is that the duration of action for the drug is approximately 6 hours. After the
release of the tourniquet, there may be detrimental decreases in blood pressure and heart rate
because the stimulus is gone, but the action of labetalol is still present. Due to this fact, many
anesthesia professionals are hesitant to give labetalol and when they do they tend to be
conservative, which may result in poor management of blood pressure and heart rate. This was
noted in the case study where the patient received 5-10 mg boluses of labetalol with very little
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lasting effect and swings in blood pressure. Labetalol is relatively inexpensive at $18.31 per 100
mg (D. Schmidt, March 25, 2016).
Esmolol. Esmolol may be a more appropriate beta blocker to attenuate the SNS response
secondary to tourniquet pain because of its short half-life of 9 minutes and its ability to be
quickly titrated as a continuous infusion (Skidmore-Roth, 2014). However, when compared to
the price of labetalol, it is relatively more expensive at $63.05 per 100 mg (D. Schmidt, personal
communication, March 25, 2016). Esmolol also does not have the sedative effects of
dexmedetomidine and potential for as smooth as an emergence in some patient populations.
Haghighi et al. (2015) preformed a randomized double blinded control study examining
the opioid reducing effects of esmolol when used in lower extremity surgery and found that
narcotic requirements were significantly decreased during surgery and in the PACU. They also
noted the stabilizing effect esmolol had on the hemodynamics of the patients. There are no
studies that compare dexmedetomidine to esmolol infusions for the attenuation of the SNS
response due to tourniquet pain.
Ketamine. Ketamine is another drug that has been shown to decrease blood pressure
during surgeries requiring a tourniquet. Park et al. (2007) examined the administration of a bolus
of 0.1 mg/kg of ketamine during general anesthesia prior to tourniquet inflation compared to a
control group. They found that the patients in the ketamine group had a significant decrease in
blood pressure during five minute intervals until the 60 minute mark where there was no
significant difference in blood pressure. It is thought that the N-methyl-D-aspartic acid (NMDA)
antagonist effects of ketamine decrease the pain response and subsequent SNS response due to
tourniquet application. No studies were found that investigated the use of a ketamine infusion,
but an infusion may result in a more stable and longer duration of blood pressure control in
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patients receiving prolonged tourniquet times. There was no mention in the literature of heart
rate control with the use of ketamine, but possible side effects of ketamine include tachycardia
and/or arrhythmias. Other side effects include nausea/vomiting, hallucination, increased intra
cranial pressure, tonic-clonic movements, and hyper salivation (Skidmore-Roth, 2014). The price
of ketamine is approximately $56.38 per 100 mg (D. Schmidt, personal communication, March
25, 2016).
Evidence Based Practice Recommendations
There appears to be enough available evidence in the literature to determine that a
dexmedetomidine infusion is beneficial in decreasing tourniquet induced hypertension and
tachycardia caused by tourniquet pain. However, it is difficult to determine the cost effectiveness
of this intervention and when it would be appropriate to implement it. When choosing an adjunct
to attenuate the SNS response related to tourniquet pain, one must consider the efficacy of the
drug, possible side effects (beneficial and harmful), and cost. Bearing this in mind, and based on
the literature review, there are two recommendations.
First, it is recommended that patients who would benefit from tight blood pressure and
heart rate control (e.g. coronary artery disease, stroke risk, increased chance of bleeding), and are
projected to receive a tourniquet time greater than 45-60 minutes while under general anesthesia
should be considered for a dexmedetomidine infusion. A bolus of 0.5-0.8 mcg/kg over 10
minutes should be initiated prior to tourniquet inflation followed by an infusion of 0.4 mcg/kg/hr
and titrated up to 1.5 mcg/kg/hr to desired effect (Lao et al., 2013). The bolus dose may be
reduced or held in those patients with labile blood pressure and/or bradycardia. Impediments for
implementation of this recommendation include cost effectiveness, possible adverse side effects,
and lack of practitioner knowledge. Dexmedetomidine is an expensive drug at about $541.28 per
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200 mcg in 50 ml normal saline (D. Schmidt, personal communication, March 25, 2016). There
is the potential that it increases post anesthesia care unit time, which may lead to higher costs,
but this controversial (Lao et al., 2013). The benefits must outweigh the expense in order for
nurse anesthetists and institutions to implement an intervention into practice. The main adverse
side effects of dexmedetomidine includes bradycardia and hypotension, but this appears to be
largely dose dependent (Alle et al., 2011; Jaideep & Bhargava, 2015; Lu et al., 2013; Lao et al.,
2013). Educating nurse anesthetists on the benefits of dexmedetomidine in prolonged tourniquet
cases will increase the likelihood of its use.
The second recommendation for practice is for nurse anesthetists to participate in and
conduct more research, ideally randomized controlled trials, related to dexmedetomidine in
prolonged tourniquet use. Although there appears to be sufficient evidence in the effectiveness of
dexmedetomidine in reducing hypertension and tachycardia in prolonged tourniquet use, there is
limited information on its cost effectiveness and potential for extending PACU times. Also, there
needs to be a comparison of beta blockers and ketamine administration in attenuating the SNS
response in prolonged tourniquet use, compared to the addition of a dexmedetomidine infusion.
The key components in these studies would be the ability to control blood pressure, heart rate,
associated side effects, and the total cost. Other trials that appeared to be absent in the review of
the literature included the use of a dexmedetomidine bolus only compared to a bolus and
infusion, and the incidence of emergence delirium in the adult population (age 18-65) having
orthopedic procedures with the addition of dexmedetomidine. Impediments to implementation of
this recommendation include the cost of research, the ethical considerations of testing
medications on patients, and the size and scope of the sample size needed to truly represent the
population.
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Conclusion
Hemodynamic stability is essential to maintain adequate organ perfusion. This is
especially true for patient populations that are at high risk for myocardial infarction, stroke, and
increased bleeding. The increased SNS response associated with tourniquet times > 45-60
minutes is difficult to control. It is refractory to narcotics and inhaled anesthetics, and
subsequently leads to hypertension and tachycardia, which can have a detrimental impact on
morbidity and mortality.
Dexmedetomidine infusions have been shown to attenuate the SNS response associated
with tourniquet pain in the literature as well as with the patient in this case report. The routine
use of dexmedetomidine in general anesthetic surgeries requiring tourniquet times greater than
45-60 minutes may be prudent, but more research needs to be done to determine the efficacy and
cost effectiveness of this intervention compared to other therapies.

DEXMEDETOMIDINE AND TOURNIQUET USE

24

References
Allee, J., Muzaffar, A., & Tobias, J. (2011). Dexmedetomidine controls the hemodynamic
manifestations of tourniquet pain. American Journal of Therapeutics, 18(2), e35-39.
Bostankolu, E., Ayoglu, H., Yurtlu, S., Okyay, R., Erdogan, G., Deniz, Y., … Turan, I. (2013).
Dexmedetomidine did not reduce the effects of tourniquet-induced ischemia-reperfusion
injury during general anesthesia. Kaohsiung J Med Sci, 29, 75–81.
http://dx.doi.org.ezproxy.undmedlibrary.org/10.1016/j.kjms.2012.08.013
Butterworth, J.F., Mackey, D.C., & Wasnick, J.D. (2013). Morgan & Mikhail’s Clinical
Anesthesiology. (5th ed.). McGraw Hill.
Cai, Y., Xu, H., Yan, J., Zhang, L., & Lu, Y. (2014). Molecular targets and mechanism of action
of dexmedetomidine in treatment of ischemia/reperfusion injury. Molecular Medicine
Reports, 9, 1542-1550. http://dx.doi.org/10.3892/mmr.2014.2034
Estebe, J., Davies, J., & Richebe, P. (2011). The pneumatic tourniquet: mechanical, ischaemia
reperfusion and systemic effects. European Journal of Anaesthesiology, 28(6), 404-411.
Haghighi, M., Sedighinejad, A., Mirbolook, A., Naderi Nabi, B., Farahmand, M., Kazemnezhad
Leili, E., … Khajeh Jahromi, S. (2015). Effect of intravenous intraoperative esmolol on
pain management following lower limb orthopedic surgery. The Korean Journal of
Pain, 28(3), 198–202.
Jaideep, C., & Bhargava, D. (2015). Good vagal tone, a tourniquet and dexmedetomidine: Recipe
for disaster. Indian Journal of Anaesthesia, 59(7), 450–451.
http://doi.org.ezproxy.undmedlibrary.org/10.4103/0019-5049.160965

DEXMEDETOMIDINE AND TOURNIQUET USE

25

Kim, D., Kim, S., So, K., & Jung, K. (2015). Effects of dexmedetomidine on smooth
emergence from anaesthesia in elderly patients undergoing orthopaedic surgery. BMC
Anesthesiology, 15, 139.
Lao, H., Tsai, P., Su, J., Kwok, T., & Huang, C. (2013). Dexmedetomidine attenuates tourniquet
induced hyperdynamic response in patients undergoing lower limb surgeries: A
randomized controlled study. Journal of Surgical Research, 179(1), 99-106.
http://dx.doi.org.ezproxy.undmedlibrary.org/10.1016/j.jss.2012.01.008
Li, Y., Wang, Y., Zhang, Y., Zheng, D., Hu, L., & Tian, M. (2015). Influence of
dexmedetomidine on the tourniquet related responses in hypertension patients receiving
unilateral knee arthroplasty under general anesthesia. The Journal of Arthroplasty,
30(8),1359-1363.
http://dx.doi.org.ezproxy.undmedlibrary.org/10.1016/j.arth.2015.02.034
Logier, R., De Jonckheere, J., Delecroix, M., Keribedi, A., Jeanne, M., Jounwaz, R., &
Tavernier, B. (2011) Heart rate variability analysis for arterial hypertension etiological
diagnosis during surgical procedures under tourniquet. Conf Proc IEEE Eng Med Biol
Soc, 3776-3779.
Lonjaret, L., Lairez, O., Minville, V., & Geeraerts, T. (2014). Optimal perioperative management
of arterial blood pressure. Integrated Blood Pressure Control, 7, 49–59.
Lu, Y., Zhang, Y., Dong, C., Yu, J., & Wong, G. T. (2013). Preoperative dexmedetomidine
prevents tourniquet-induced hypertension in orthopedic operation during general
anesthesia. The Kaohsiung Journal of Medical Sciences, 29(5), 271-274.
http://dx.doi.org.ezproxy.undmedlibrary.org/10.1016/j.kjms.2012.09.006
Nagelhout J.J., & Plaus K.L. (2014). Nurse Anesthesia (5th ed.). Elsevier Saunders.

DEXMEDETOMIDINE AND TOURNIQUET USE

26

Park, J., Jung, Y., Baek C., Kang, H., & Cha, S. (2007). Effects of low-dose ketamine on
tourniquet induced haemodynamic responses during general anaesthesia. The Journal of
International Medical Research, 35(5), 600-608.
Sharma, J. P., & Salhotra, R. (2012). Tourniquets in orthopedic surgery. Indian Journal of
Orthopaedics, 46(4), 377–383.
Skidmore-Roth, L. (2014). Mosby’s 2015 Nursing Drug Reference (28th ed.). St. Louis:
Elsevier/Mosby.
Wong, S., & Irwin, M. (2016), Peri-operative cardiac protection for non-cardiac surgery.
Anaesthesia, 71, 29–39.
Yagmurdur, H., Ozcan, N., Dokumacı, F., Kilinc, K., Yilmaz, F., & Basar H. (2008).
Dexmedetomidine reduces the ischemia-reperfusion injury markers during upper
extremity surgery with tourniquet. J Hand Surg, 33, 941–947.
http://dx.doi.org.ezproxy.undmedlibrary.org/10.1016/j.jhsa.2008.01.014

DEXMEDETOMIDINE AND TOURNIQUET USE

27

DEXMEDETOMIDINE AND TOURNIQUET USE

28

DEXMEDETOMIDINE AND TOURNIQUET USE

29

DEXMEDETOMIDINE AND TOURNIQUET USE

30

